Mood:

Now Playing: laptop crunching away
Topic: School
I haven't revised it yet, but it is FINISHED!! Well, okay, I went over it once, but haven't printed it out to really LOOK at it. I guess that it's taken me about... hmm... 9 or 10 hours? That sounds about right. ANyway, here it is:
SSRI Medications: Friend or Foe?
Lauren Grande
Psychology 111, Section 400
Professor Clagett
November 29, 2004
Abstract
SSRI medications are most commonly prescribed for treating depression. These medications have also been proven successful in depression remission and have enabled sufferers of this illness to live more fulfilling lives. Unfortunately, SSRIs also have a number of undesirable side effects, which may cause anything from mild discomfort to death, in the most extreme cases. Patients and their doctors must ultimately decide what treatments options are best for them, and whether taking an SSRI medication is worth the risk.
SSRI Medications: Friend or Foe?
Depression is a devastating mental illness that harmfully affects millions of Americans each year. Unfortunately, it is often left untreated, resulting in thousands of deaths due to suicide annually in our country. It is regrettable that so many people resort to suicide, since most cases of depression can be effectively treated through antidepressant therapy, psychotherapy, electroconvulsive (ECT) therapy, or a combination of these methods. We are constantly bombarded with advertisements for antidepressant medications, commonly of the newer class of drugs called selective serotonin reuptake inhibitors (SSRIs). Selective serotonin reuptake inhibitors have been proven effective for the treatment of depression, but are they the best option? After a careful investigation of these medications, the patient and their doctor(s) must decide whether the benefits of taking SSRIs outweigh the risks and side effects.
Society wants a quick fix; a magic pill. Today, SSRIs are viewed as that magic pill. SSRIs made their first appearance in 1987 with the FDA approval of Prozac (fluoxetine). Prozac is one of the most commonly prescribed medications and has been prescribed to more than 40 million people worldwide (Prozac). How do Prozac and other SSRIs cure depression? According to Prozac's website:
[A] growing amount of evidence supports the view that people with depression have an imbalance of the brain's neurotransmitters, the chemicals that allow nerve cells in the brain to communicate with each other. Many scientists believe that an imbalance in serotonin, one of these neurotransmitters, may be an important factor in the development and severity of depression. PROZAC may help to correct this imbalance by increasing the brain's own supply of serotonin. Some other antidepressant medicines appear to affect several neurotransmitters in addition to serotonin. PROZAC selectively affects only serotonin. ("Prozac")
Eli Lilly, makers of Prozac, struck gold when the company discovered this drug. Since Prozac has been so effective at treating depression, other pharmaceutical companies have followed suit and developed their own medications.
At least seven new SSRI medications have gone on the market since Prozac was first introduced. These medications include Celexa (citalopram), Cymbalta (duloxetine), Effexor (venlafaxine), Lexapro (escitalopram), Luvox (fluvoxamine), Paxil (paroxetine), and Zoloft (sertraline). Dr. Dennis Charney, M.D., Chief of Mood and Anxiety Disorder Research Program at NIMH and Dr. Charles Nemeroff, M.D., Ph.D., of Emory University School of Medicine discuss Celexa: "Celexa is a selective serotonin reuptake inhibitor (SSRI). The Celexa molecule more selectively targets the serotonin reuptake pumps than most other SSRIs do. It is as effective as other SSRIs and has similar side effects" (Charney and Nemeroff 106). What are these side effects? Celexa reports that the most frequent side effects reported are nausea, dry mouth, drowsiness, insomnia, increased sweating, tremor, diarrhea, and problems with ejaculation ("Celexa"). Although they claim that some patients notice an improvement (after taking Celexa) in as little as one week, as with most SSRI medications, Celexa states that most patients feel better after four to six weeks.
Cymbalta is a recent addition (2004) to the medication market and boosts levels of both serotonin and norepinephrine (another neurotransmitter implicated in the treatment of depression). In studies, this drug has had relatively mild side effects including nausea, dry mouth, constipation, decreased appetite, fatigue, sleepiness and increased sweating ("FDA Approves Lilly's Cymbalta"). According to an article published by the Associated Press, "Cymbalta is approved to treat major depression for up to nine weeks. In one study, Cymbalta users were almost three times as likely to achieve remission of their depression as patients given a dummy pill, said Lilly's Dr. Madelaine Wohlreich" (AP "FDA approves new antidepressant"). However, in February a college student taking part in a study of the drug hung herself in a company research facility. Lilly maintains that there's no evidence that the drug was to blame.
The next SSRI we will explore is Effexor, which raises the levels of serotonin and norepinephrine, like Cymbalta. Dr. Charney and Dr. Nemeroff state that "some patients, particularly those with severe depression, seem to respond better to Effexor than to medications that work primarily on only one neurotransmitter, though it may also produce a wider range of side effects" (Charney and Nemeroff 107). A check of the listed side effects of Effexor confirms Charney and Nemeroff's statements regarding side effects: nausea, vomiting, upset stomach, abdominal pain, or loss of appetite or weight; dry mouth; drowsiness or dizziness; mild tremor, anxiety, or agitation; insomnia; abnormal dreams; sexual problems such as impotence, abnormal ejaculation, difficulty reaching orgasm, or decreased libido; sweating; yawning; or increase in blood cholesterol levels ("Venlafaxine"). After viewing this list, it's not surprising that people often stop taking their medication due to negative side effects.
Lexapro is similar to Celexa and is made by the same company, Forest Pharmaceuticals. While Celexa contains two chemically similar molecules that raise serotonin levels, Lexapro only contains one of those molecules, which makes Lexapro effective at lower doses and is believed to have a reduced amount of side effects. Nausea, insomnia, problems with ejaculation, somnolence, increased sweating, fatigue, decreased libido, and anorgasma (inability to achieve orgasm) are the most commonly reported side effects ("About Lexapro").
We continue our journey through the pharmaceutical jungle with an examination of Luvox. According to Charney and Nemeroff, Luvox is an SSRI primarily used for treating obsessive-compulsive disorder (OCD), but is also effective for depression. The side effects of Luvox are consistent with most other SSRIs; insomnia, sleepiness, nausea, weakness, sexual dysfunction, nervousness, dry mouth, and constipation (National Alliance for the Mentally Ill [NAMI]).
Paxil is one of the most controversial drugs currently on the market; it was one of the first drugs that sparked debate over whether SSRI medications should be taken by children under 18. GlaxoSmithKline, the company that produces Paxil informs us of the side effects that have become all too familiar: nausea, injury, infection, diarrhea, constipation, decreased appetite, sleepiness, dizziness, yawning, sweating, abnormal vision, and sexual side effects ("Questions about Paxil"). What they mean by "injury" isn't clear, but it certainly does not sound like a positive side effect. Nevertheless, like its other SSRI counterparts, Paxil is an effective treatment for medication and many patients have found relief from their symptoms by taking it.
Finally, we arrive at Zoloft, which not only increases serotonin levels, but is believed to increase dopamine levels at higher doses. The increased dopamine levels has an energizing effect, which makes Zoloft a quality choice for people who feel lethargic. Following are the common side effects associated with Zoloft: upset stomach, difficulty sleeping, diarrhea, dry mouth, sexual side effects, feeling unusually sleepy or tired, tremor, indigestion, increase of sweating, feeling agitated, and decreased appetite ("How Zoloft can Help"). In addition to treating depression, Zoloft is also commonly prescribed for panic disorder, social anxiety disorder, obsessive-compulsive disorder, and posttraumatic stress disorder.
After learning the side effects of all of these medications, someone who is uneducated about depression might wonder why anyone would take these drugs. Unfortunately, depression can be an incapacitating illness and those afflicted with the disorder will go to any length to stop the pain. In most cases, this means either seeking treatment or resorting to suicide. According to the Depression and Bipolar Support Alliance (DBSA), if you experience five or more of the following symptoms for more than two weeks, or if any of these symptoms interfere with work or family activities, consult with your doctor for an evaluation:
Symptoms of depression include prolonged sadness or unexplained crying spells; significant changes in appetite and sleep patterns; irritability, anger, worry, agitation, anxiety; pessimism, indifference; loss of energy, persistent lethargy; feelings of guilt, worthlessness; inability to concentrate, indecisiveness; inability to take pleasure in former interests, social withdrawal; unexplained aches and pains; and recurring thoughts of death or suicide. (DBSA)
It is no wonder that these symptoms can overshadow the risk of side effects from SSRI medications.
Many patients taking SSRI medications do not experience negative side effects. When side effects do occur, they are usually not severe enough to cause the patient to discontinue treatment. Charney and Nemeroff explain:
Adverse events, of course, can occur after the administration of any drug, antidepressants included, and over the past few decades a handful of patients have experienced some unusual side effects, such as rashes, abdominal pain, agitation, and marked sleepiness. But such reactions are very rare and shouldn't deter people from trying antidepressants; every risk-benefit analysis done to date has shown the remarkable benefits of using these agents. (Charney and Nemeroff 106)
Since many experts in the psychiatry field are convinced that the benefits outweigh the risks, patients are often prescribed these drugs and aren't too concerned about side effects.
There are some exceptional examples of how these drugs have had a positive impact on the lives of patients suffering from depression. Dr. William S. Appleton, M.D. of Harvard Medical School shares the story of Laura, who moved to a new city and became depressed after not adjusting to her new surroundings:
A thirty-six-year-old stranger in a new city, Laura burst into tears at work, and felt lonely, less capable than the other middle managers, and unable to attract a suitable man. Prozac steadily raised her level of confidence and stopped her tears. Feeling better for six months, she decided to stop taking the drug, but her improvement continued. Performing well at work, she was promoted. She fell in love and has plans to marry. (Appleton 95)
According to Appleton, depressed people are negative about their lives - past, present, and future. They have no hope for any of this and are unable to plan their lives. He says that without hope, they are plagued by passivity and indecision. These things make the depressed person feel ineffective and worthless - it is a continuing downward spiral. SSRI medications restore hope for most patients, which results in the person being able to plan social activities, make decisions, and generally begin feeling good about the things that they can now accomplish (Appleton 92). This class of antidepressants has been lifesaving for many people, and the positive effects must not be discounted.
Regrettably, SSRI medications have come under fire recently for a believed increase in suicidal ideation and behavior in adolescents, and also a discontinuation or withdrawal syndrome in patients who stop taking the medication suddenly. On October 15, 2004, the Food and Drug Administration (FDA) issued a Public Health Advisory announcing a strategy to warn the public about suicidality in children and adolescents being treated with antidepressants, the list being made up of mostly SSRI medications. Their press release states:
In letters issued today, FDA directed the manufacturers of all antidepressant medications to add a "black box" warning that describes the increased risk of suicidality in children and adolescents given antidepressant medications and notes what uses the drugs have been approved or not approved for in these patients [...] A "black box" warning is the most serious warning placed in the labeling of a prescription medication. Advertisements that serve to remind health care professionals of a product's availability (so-called "reminder ads") are not allowed for products with "black box" warnings. Until now, only ten drug products approved for children contained a black box warning about their use in children. The new warning language does not prohibit the use of antidepressants in children and adolescents. Rather, it warns of the risk of suicidality and encourages prescribers to balance this risk with clinical need. (FDA)
Will this notice alarm parents; preventing children and adolescents from receiving the treatment that they need? Many experts in the psychiatry field are concerned about that issue.
One such expert is David Fassler, M.D., a trustee of the American Psychiatric Association (APA). He was at the FDA advisory panel's February 2, 2004 public hearing, and made the following comments:
"We are concerned that the publicity surrounding this issue may frighten some parents and discourage them from seeking help from their children. This would be a real tragedy, since the reality is that we really can help most kids who suffer from psychiatric disorders, including childhood and adolescent depression. The most important point that I can make is that the biggest risk for a child with depression is to be left untreated." (Jackim 32)
Comparisons have been drawn in the psychiatric community between "the slaughtering of one type of cow across the country due to the mad cow scare instead of increasing the testing and tracking [of the animals]" (Dr. John Rose, qtd. In Jackim 32). Perhaps there can be a compromise reached in these cases, and all parties involved can reach an agreement.
The recent FDA warnings on SSRI medications only comprise one part of the dilemma, however. Another trouble with SSRI medications is the problem of withdrawal reactions. A case is given in the American Family Physician journal of a patient who experienced withdrawal reactions after discontinuing Zoloft (sertraline):
The patient, a 43-year-old man, had been treated for depression with sertraline for about six months and was taking a maintenance dosage of 25 mg per day. Because the patient experienced drowsiness, the dosage was tapered to 12.5 mg per day for a week and then stopped. The patient began taking venlafaxine [Effexor], 37.5 mg, one-half tablet twice daily. Within 48 hours of discontinuing the sertraline, he noticed the onset of severe dizziness and lightheadedness, aggravated by sudden changes in position but without a sensation of spinning or nausea. Venlafazine was discontinued after five days without relief of symptoms. When the dizziness persisted for another week, sertraline was restarted at a dosage of 12.5 mg at bedtime, and the dizziness and lightheadedness ceased by the following morning. He was subsequently tapered slowly from the sertraline with no further symptoms. (Wolfe 455)
Patients experiencing SSRI medication withdrawal may have symptoms worse than their known side effects. Those side effects read like a medical encyclopedia: abdominal pain, anorexia, diarrhea, dry mouth, increased appetite, nausea, vomiting, blurry or double vision, chest discomfort, chills, coryza, fatigue, flu-like syndrome, headache, malaise, myalgia, sweating, weakness, palpitations, postural hypotension, disorientation, dizziness or vertigo, dyskinesia and dystonia, imbalance, jitteriness/tremor, impaired memory or thinking, paresthesias (burning, tingling or electric shock sensations in spine or perioral area), Lhermitte's sign (electric shock sensation in spine or limbs, elicited by neck flexion), transient "rushing" or "buzzing" in head, migraine-like scotomas, tinnitus, excessive, vivid and early-onset dreaming, insomnia, nightmares, anxiety, apathy, aggressiveness, confusion, depersonalization, hallucinations, lowered mood or depression, hypomania, irritability, and panic (Wolfe 459). Not all patients develop these symptoms after sudden cessation of SSRI use, but according to Dr. Kara E. Ditto, M.D., M.P.H., "discontinuation syndrome [...] is experienced by up to 25% of patients who abruptly quit taking these agents" (Ditto). While this figure means that roughly seventy-five percent of patients using SSRIs experience no withdrawal effects, the number of those suffering from withdrawal is still a contemptible amount.
There have also been class action suits filed against the pharmaceutical companies that manufacture these drugs. One particular suit against the makers of Paxil, GlaxoSmithKline, Inc., filed by Katherine Keith et al. in California makes the claim:
Thousands of Paxil users suffer dependency/withdrawal syndrome [...] Over the past two (2) years, plaintiff's attorneys have been individually contact by approximately 500 Paxil withdrawal victims. The pain and suffering experienced by each of these individuals is the direct result of GLAXOSMITHKLINE CORPORATION's failure to warn users of Paxil's addictive nature, the drug's inducement of physical or psychologic dependency, and its infliction of dependency/withdrawal syndrome when the patient's Paxil dosage is reduced or terminated. (Baum, Hedlund, Aristei, Guilford & Schiavo)
There are more cases all over the country, both class action lawsuits and individual cases that include a range of SSRI medications; Paxil, Prozac, Effexor, Luvox, and Zoloft. Does this mean that Cymbalta, Celexa and Lexapro are out of the woods yet? Probably not, since these are all relatively new medications and will require more time for a definitive outcome to treatment, either positive or negative.
Should SSRI medications be outlawed? Some medications certainly require closer review by the FDA. These medications are effective at treating depression, and should be used by those who are able to make an informed decision about their treatment. Parents of children on SSRI medications need to pay careful attention to the FDA reports on these drugs, but they should also beware of the consequences that may arise should their child stop taking their medication. There are many routes of treatment available for those with depression; SSRI medications are only one of them. SSRI medications can be used to treat depression, but only after all of the risks and benefits have been weighed.
References
About Lexapro. (n.d.). Retrieved November 27, 2004 from
http://www.lexapro.com/english/about_lexapro/default.aspx
About Medications: Luvox. (June 2003). Retrieved November 27, 2004 from
http://www.nami.org/Template.cfm?Section=About_Medications
Appleton, W. (2000). Prozac and the New Antidepressants. New York: Penguin Books.
Associated Press. (August 4, 2004). FDA approves new antidepressant. CNN. Retrieved
November 27, 2004 from http://www.cnn.com
Baum, Hedlund, Aristei, Guilford & Schiavo. (August 23, 2001). Katherine Keith et al.
vs. GlaxoSmithKline, Inc. Retrieved November 27, 2004 from
http://www.baumhedlundlaw.com/media/ssri/paxil/paxil_complaint.pdf
Charney, D. & Nemeroff, C. (2004). The Peace of Mind Prescription. New York: Houghton
Mifflin.
Depression Facts, Symptoms, and Treatment. (November 22, 2004). Retrieved November 26, 2004 from http://www.dbsalliance.org/info/depression.html
Ditto, K. (August 2003). SSRI discontinuation syndrome: awareness as an approach to
prevention. Retrieved November 22, 2004 from http://www.postgradmed.com/issues/2003/08_03/ditto.htm
FDA Approves Lilly's Cymbalta for the Treatment of Depression. (August 4, 2004).
Retrieved November 27, 2004 from
http://newsroom.lilly.com/news/Product/2004-08-04_fda_approves_cymbalta.html
FDA Launches a Multi-Pronged Strategy to Strengthen Safeguards for Children Treated with
Antidepressant Medications. (October 15, 2004). Retrieved November 28, 2004 from http://www.fda.gov/bbs/topics/news/2004/new01124.html
How Prozac Can Help: Safety Facts. (n.d.). Retrieved November 26, 2004 from http://www.prozac.com/how_prozac/safety_facts.jsp?reqNavId=2.5
How Zoloft can Help. (2004). Retrieved November 27, 2004 from
http://www.zoloft.com/index.asp?pageid=44
Jackim, L. (April 2004). Clinicians say they're twisting in wind during FDA review of SSRIs.
Behavioral Healthcare Tomorrow, 13(2), 31-34.
Mundell, E.J. (September 15, 2004) Antidepressant Warning Might Keep Kids from Care.
Retrieved November 27, 2004 from http://www.med.miami.edu/communications/som_news/index.asp?id=267
Questions About Paxil. (n.d.). Retrieved November 27, 2004 from
http://www.paxil.com/about/nw_pxl.html
SSRI Withdrawal Syndrome. (1996). Retrieved November 26, 2004 from http://psychiatry.jwatch.org/cgi/content/full/1996/1201/1
Venlafaxine. (April 7, 2004). Retrieved November 27, 2004 from
http://content.health.msn.com/hw/drug_data/d03181a1?bn=effexor
What to Expect. (n.d.). Retrieved November 26, 2004 from
http://www.celexa.com/about_celexa/what_to_expect.asp
Wolfe, R. (August 1997). Antidepressant withdrawal reactions. American Family
Physician, 56, 455-463.
posted by a cautiously optimistic Redskins fan
at 6:21 PM EST